141 related articles for article (PubMed ID: 34554822)
1. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
[No Abstract] [Full Text] [Related]
2. Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki Y; Shimomura A; Yoshimura K; Terakado H; Shimizu C
J Clin Oncol; 2021 Nov; 39(31):3521-3522. PubMed ID: 34554850
[No Abstract] [Full Text] [Related]
3. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
[TBL] [Abstract][Full Text] [Related]
4. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
Dent R; Rugo HS
Lancet Oncol; 2021 Jan; 22(1):27-28. PubMed ID: 33387495
[No Abstract] [Full Text] [Related]
5. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.
Laird J; Leventhal J; Kanowitz J; Damast S
Pract Radiat Oncol; 2021; 11(6):448-452. PubMed ID: 34157449
[TBL] [Abstract][Full Text] [Related]
6. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.
Poggio F; Tagliamento M; Ceppi M; Bruzzone M; Conte B; Fregatti P; Punie K; de Azambuja E; Del Mastro L; Lambertini M
Ann Oncol; 2022 Mar; 33(3):347-349. PubMed ID: 34861375
[No Abstract] [Full Text] [Related]
7. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
Tomasik B; Bieńkowski M; Jassem J
Ann Oncol; 2022 Jun; 33(6):658-659. PubMed ID: 35306157
[No Abstract] [Full Text] [Related]
8. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Guven DC; Taban H; Dizdar O
J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
[No Abstract] [Full Text] [Related]
10. [Not Available].
Gonçalves A
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
[TBL] [Abstract][Full Text] [Related]
12. Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Rediti M; Messina C
Breast Cancer Res Treat; 2018 Nov; 172(1):239-240. PubMed ID: 30003394
[No Abstract] [Full Text] [Related]
13. Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
Olivier T; Prasad V
Ann Oncol; 2023 Aug; 34(8):723-724. PubMed ID: 37423675
[No Abstract] [Full Text] [Related]
14. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
van Dongen MGJ; Kok M
Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
[No Abstract] [Full Text] [Related]
15. Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
Kubouchi K; Shimada K; Yokoe T; Tsutsumi Y
Technol Cancer Res Treat; 2020; 19():1533033820943246. PubMed ID: 32677589
[TBL] [Abstract][Full Text] [Related]
16. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
Minot-This MS; Deleuze A
Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
[No Abstract] [Full Text] [Related]
17. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.
Marra A; Curigliano G
Cancer J; 2021 Jan-Feb 01; 27(1):41-49. PubMed ID: 33475292
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
19. How shall we treat locally advanced triple negative breast cancer?
Luz P; Dias D; Fortuna A; Bretes L; Gosalbez B
F1000Res; 2019; 8():1649. PubMed ID: 32802311
[TBL] [Abstract][Full Text] [Related]
20. Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
Agostinetto E; Buisseret L; Salgado R; Kok M; Ignatiadis M
Ann Oncol; 2024 May; 35(5):409-411. PubMed ID: 38484973
[No Abstract] [Full Text] [Related]
[Next] [New Search]